|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBE2K |
Gene summary for UBE2K |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBE2K | Gene ID | 3093 |
| Gene name | ubiquitin conjugating enzyme E2 K | |
| Gene Alias | E2-25K | |
| Cytomap | 4p14 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | P61086 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3093 | UBE2K | CA_HPV_1 | Human | Cervix | CC | 4.67e-02 | 1.54e-02 | 0.0264 |
| 3093 | UBE2K | CCI_2 | Human | Cervix | CC | 1.16e-10 | 1.03e+00 | 0.5249 |
| 3093 | UBE2K | CCI_3 | Human | Cervix | CC | 3.17e-06 | 6.87e-01 | 0.516 |
| 3093 | UBE2K | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.14e-09 | -4.15e-01 | 0.0155 |
| 3093 | UBE2K | HTA11_347_2000001011 | Human | Colorectum | AD | 2.66e-15 | 6.43e-01 | -0.1954 |
| 3093 | UBE2K | HTA11_83_2000001011 | Human | Colorectum | SER | 6.92e-03 | 4.88e-01 | -0.1526 |
| 3093 | UBE2K | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.89e-02 | 4.28e-01 | -0.059 |
| 3093 | UBE2K | F007 | Human | Colorectum | FAP | 1.72e-02 | -2.43e-01 | 0.1176 |
| 3093 | UBE2K | A001-C-207 | Human | Colorectum | FAP | 1.70e-04 | -2.98e-01 | 0.1278 |
| 3093 | UBE2K | A015-C-203 | Human | Colorectum | FAP | 5.66e-38 | -4.95e-01 | -0.1294 |
| 3093 | UBE2K | A015-C-204 | Human | Colorectum | FAP | 1.60e-07 | -3.73e-01 | -0.0228 |
| 3093 | UBE2K | A014-C-040 | Human | Colorectum | FAP | 1.65e-06 | -4.91e-01 | -0.1184 |
| 3093 | UBE2K | A002-C-201 | Human | Colorectum | FAP | 5.40e-17 | -3.11e-01 | 0.0324 |
| 3093 | UBE2K | A002-C-203 | Human | Colorectum | FAP | 8.89e-06 | -2.53e-01 | 0.2786 |
| 3093 | UBE2K | A001-C-119 | Human | Colorectum | FAP | 1.68e-07 | -8.62e-02 | -0.1557 |
| 3093 | UBE2K | A001-C-108 | Human | Colorectum | FAP | 8.42e-20 | -3.74e-01 | -0.0272 |
| 3093 | UBE2K | A002-C-205 | Human | Colorectum | FAP | 1.17e-27 | -3.93e-01 | -0.1236 |
| 3093 | UBE2K | A001-C-104 | Human | Colorectum | FAP | 1.18e-05 | -2.39e-01 | 0.0184 |
| 3093 | UBE2K | A015-C-005 | Human | Colorectum | FAP | 1.57e-04 | -2.98e-01 | -0.0336 |
| 3093 | UBE2K | A015-C-006 | Human | Colorectum | FAP | 3.96e-21 | -3.59e-01 | -0.0994 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000020915 | Oral cavity | LP | protein polyubiquitination | 82/4623 | 236/18723 | 3.23e-04 | 3.26e-03 | 82 |
| GO:003320913 | Oral cavity | LP | tumor necrosis factor-mediated signaling pathway | 38/4623 | 99/18723 | 1.72e-03 | 1.31e-02 | 38 |
| GO:003545612 | Oral cavity | LP | response to interferon-beta | 16/4623 | 32/18723 | 1.73e-03 | 1.32e-02 | 16 |
| GO:003461219 | Oral cavity | LP | response to tumor necrosis factor | 83/4623 | 253/18723 | 2.10e-03 | 1.54e-02 | 83 |
| GO:00108031 | Oral cavity | LP | regulation of tumor necrosis factor-mediated signaling pathway | 21/4623 | 47/18723 | 2.17e-03 | 1.58e-02 | 21 |
| GO:000196111 | Oral cavity | LP | positive regulation of cytokine-mediated signaling pathway | 22/4623 | 50/18723 | 2.18e-03 | 1.58e-02 | 22 |
| GO:007135619 | Oral cavity | LP | cellular response to tumor necrosis factor | 76/4623 | 229/18723 | 2.24e-03 | 1.62e-02 | 76 |
| GO:006076011 | Oral cavity | LP | positive regulation of response to cytokine stimulus | 24/4623 | 57/18723 | 2.88e-03 | 2.00e-02 | 24 |
| GO:190326512 | Oral cavity | LP | positive regulation of tumor necrosis factor-mediated signaling pathway | 7/4623 | 11/18723 | 7.01e-03 | 3.96e-02 | 7 |
| GO:009719326 | Oral cavity | EOLP | intrinsic apoptotic signaling pathway | 84/2218 | 288/18723 | 1.29e-15 | 7.05e-13 | 84 |
| GO:007093622 | Oral cavity | EOLP | protein K48-linked ubiquitination | 31/2218 | 65/18723 | 9.08e-13 | 2.27e-10 | 31 |
| GO:001049825 | Oral cavity | EOLP | proteasomal protein catabolic process | 108/2218 | 490/18723 | 7.79e-11 | 9.51e-09 | 108 |
| GO:000283121 | Oral cavity | EOLP | regulation of response to biotic stimulus | 80/2218 | 327/18723 | 1.31e-10 | 1.43e-08 | 80 |
| GO:005125825 | Oral cavity | EOLP | protein polymerization | 74/2218 | 297/18723 | 2.65e-10 | 2.45e-08 | 74 |
| GO:00607592 | Oral cavity | EOLP | regulation of response to cytokine stimulus | 49/2218 | 162/18723 | 2.70e-10 | 2.45e-08 | 49 |
| GO:004217626 | Oral cavity | EOLP | regulation of protein catabolic process | 90/2218 | 391/18723 | 2.92e-10 | 2.58e-08 | 90 |
| GO:003497624 | Oral cavity | EOLP | response to endoplasmic reticulum stress | 66/2218 | 256/18723 | 5.33e-10 | 4.31e-08 | 66 |
| GO:00019592 | Oral cavity | EOLP | regulation of cytokine-mediated signaling pathway | 46/2218 | 150/18723 | 5.71e-10 | 4.44e-08 | 46 |
| GO:000020923 | Oral cavity | EOLP | protein polyubiquitination | 62/2218 | 236/18723 | 7.88e-10 | 5.90e-08 | 62 |
| GO:004316125 | Oral cavity | EOLP | proteasome-mediated ubiquitin-dependent protein catabolic process | 92/2218 | 412/18723 | 9.87e-10 | 6.96e-08 | 92 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
| hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
| hsa04120 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
| hsa041201 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
| hsa041202 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
| hsa041203 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
| hsa041206 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
| hsa041207 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
| hsa041208 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
| hsa041209 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
| hsa0412016 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
| hsa0412017 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
| hsa0412023 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
| hsa0412033 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
| hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
| hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
| hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa0412010 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
| hsa0412011 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBE2K | SNV | Missense_Mutation | novel | c.501A>C | p.Glu167Asp | p.E167D | P61086 | protein_coding | tolerated(0.53) | benign(0) | TCGA-AA-3814-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| UBE2K | SNV | Missense_Mutation | c.220N>T | p.Arg74Trp | p.R74W | P61086 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UBE2K | SNV | Missense_Mutation | rs199792616 | c.320N>A | p.Arg107His | p.R107H | P61086 | protein_coding | deleterious(0) | possibly_damaging(0.52) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| UBE2K | SNV | Missense_Mutation | c.369N>A | p.Asp123Glu | p.D123E | P61086 | protein_coding | deleterious(0.01) | benign(0.198) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| UBE2K | SNV | Missense_Mutation | c.458C>T | p.Ala153Val | p.A153V | P61086 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| UBE2K | SNV | Missense_Mutation | c.248A>G | p.Asn83Ser | p.N83S | P61086 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AF-6655-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| UBE2K | SNV | Missense_Mutation | c.275G>A | p.Cys92Tyr | p.C92Y | P61086 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EI-6509-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| UBE2K | SNV | Missense_Mutation | c.378N>T | p.Gln126His | p.Q126H | P61086 | protein_coding | deleterious(0) | probably_damaging(0.954) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| UBE2K | SNV | Missense_Mutation | novel | c.209N>A | p.Pro70His | p.P70H | P61086 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| UBE2K | SNV | Missense_Mutation | c.206N>C | p.Asn69Thr | p.N69T | P61086 | protein_coding | tolerated(0.13) | benign(0.038) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |